701 related articles for article (PubMed ID: 29290074)
1. Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase®.
Svendsen K; Wood M; Olsson E; Nordeng H
Eur J Clin Pharmacol; 2018 May; 74(5):627-636. PubMed ID: 29290074
[TBL] [Abstract][Full Text] [Related]
2. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
[TBL] [Abstract][Full Text] [Related]
3. Reported Adverse Drug Reactions in Children and Adolescents Treated with Antipsychotics.
Minjon L; van den Ban E; de Jong E; Souverein PC; Egberts TCG; Heerdink ER
J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):124-132. PubMed ID: 30676073
[TBL] [Abstract][Full Text] [Related]
4. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
[TBL] [Abstract][Full Text] [Related]
5. Adverse drug reactions in Nigerian children: a retrospective review of reports submitted to the Nigerian Pharmacovigilance Centre from 2005 to 2012.
Obebi Cliff-Eribo K; Sammons H; Star K; Ralph Edwards I; Osakwe A; Choonara I
Paediatr Int Child Health; 2016 Nov; 36(4):300-304. PubMed ID: 26384567
[TBL] [Abstract][Full Text] [Related]
6. Adverse drug reactions in Ghanaian children: review of reports from 2000 to 2012 in VigiBase.
Cliff-Eribo KO; Choonara I; Dodoo A; Darko DM; Sammons H
Expert Opin Drug Saf; 2015; 14(12):1827-33. PubMed ID: 26436964
[TBL] [Abstract][Full Text] [Related]
7. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.
Conte C; Rousseau V; Vert C; Montastruc F; Montastruc JL; Durrieu G; Olivier P
Fundam Clin Pharmacol; 2020 Aug; 34(4):518-520. PubMed ID: 32022302
[TBL] [Abstract][Full Text] [Related]
8. Current Status of Parkinsonism-Related Adverse Events and Associated Drugs in Korea.
Kim S; Suh HS
J Patient Saf; 2019 Dec; 15(4):e56-e59. PubMed ID: 28368965
[TBL] [Abstract][Full Text] [Related]
9. Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase.
Star K; Norén GN; Nordin K; Edwards IR
Drug Saf; 2011 May; 34(5):415-28. PubMed ID: 21513364
[TBL] [Abstract][Full Text] [Related]
10. Safety profile of H1-antihistamines in pediatrics: an analysis based on data from VigiBase.
Motola D; Donati M; Biagi C; Calamelli E; Cipriani F; Melis M; Monaco L; Vaccheri A; Ricci G
Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1164-1171. PubMed ID: 28653802
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of adverse reactions and pharmacovigilance research to parenterally administered shuxuening].
Yang W; Xiang YY; Xie YM; Shen H
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3013-8. PubMed ID: 24471322
[TBL] [Abstract][Full Text] [Related]
12. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital.
Jose J; Rao PG
Pharmacol Res; 2006 Sep; 54(3):226-33. PubMed ID: 16781163
[TBL] [Abstract][Full Text] [Related]
13. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
[TBL] [Abstract][Full Text] [Related]
14. [Knowledge creation about adverse drug reactions in the paediatric population].
Aagaard L
Ugeskr Laeger; 2013 Feb; 175(6):342-5. PubMed ID: 23402239
[TBL] [Abstract][Full Text] [Related]
15. Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.
Kröger E; Mouls M; Wilchesky M; Berkers M; Carmichael PH; van Marum R; Souverein P; Egberts T; Laroche ML
Ann Pharmacother; 2015 Nov; 49(11):1197-206. PubMed ID: 26324356
[TBL] [Abstract][Full Text] [Related]
16. Adverse drug reaction monitoring: support for pharmacovigilance at a tertiary care hospital in Northern Brazil.
Lobo MG; Pinheiro SM; Castro JG; Momenté VG; Pranchevicius MC
BMC Pharmacol Toxicol; 2013 Jan; 14():5. PubMed ID: 23298396
[TBL] [Abstract][Full Text] [Related]
17. Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database.
Kumlien E; Lundberg PO
Seizure; 2010 Mar; 19(2):69-73. PubMed ID: 20036167
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
19. The value of time-to-onset in statistical signal detection of adverse drug reactions: a comparison with disproportionality analysis in spontaneous reports from the Netherlands.
Scholl JH; van Puijenbroek EP
Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1361-1367. PubMed ID: 27686554
[TBL] [Abstract][Full Text] [Related]
20. A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence.
Sharma PK; Misra AK; Gupta A; Singh S; Dhamija P; Pareek P
Indian J Pharmacol; 2018; 50(5):273-278. PubMed ID: 30636831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
